Claire Langlade1,2, Amandine Gouverneur1,2, Pauline Bosco-Lévy1,3, Aurore Gouraud4, Marie-Christine Pérault-Pochat5, Johana Béné6, Ghada Miremont-Salamé1,2, Antoine Pariente1,2. 1. Univ. Bordeaux, Inserm, Bordeaux Population Health Research Centre, team PHARMACOEPIDEMIOLOGY, UMR 1219, Bordeaux, France. 2. Pôle de santé publique, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance de Bordeaux, CHU de Bordeaux, Bordeaux, France. 3. INSERM CIC1401, Bordeaux PharmacoEpi, Bordeaux, France. 4. Service Hospitalo-Universitaire de Pharmacotoxicologie, CHU de Lyon, Lyon, France. 5. Pharmacologie clinique et vigilances, LNEC, INSERM U1084, CHU de Poitiers, Poitiers, France. 6. Centre de pharmacovigilance du Nord Pas de Calais, 1 place de Verdun, Lille, France.
Abstract
AIMS: In 2017, concerns regarding adverse events (AEs) associated with the Mirena levonorgestrel intrauterine device were largely echoed in the media in France. This resulted in a tremendous reporting of AEs to pharmacovigilance centres. The aim of this study was to describe the reporting of AEs regarding Mirena in France and to study the impact of media coverage on this reporting. METHODS: All cases reports involving Mirena recorded in the French national pharmacovigilance database from marketing (21 July 1995) until 04 August 2017 were extracted. To allow studying the influence of mediatisation, reports were described separately for the periods preceding and following the observed media coverage peak (15 May 2017). RESULTS: Overall, 3224 reports were considered, 510 (15.8%) recorded before the media coverage peak, and 2714 (84.2%) after. Before the peak, 76.5% of reports originated from health professionals; median time-to-report was of 5.5 months (interquartile range: 1.7-18.6), and median number of AEs per report was 1 (range: 1-17). After the peak, 98.6% originated from patients; median time-to-report was 21 months (interquartile range: 8.1-45.5), and median number of AEs per report was 6 (range: 1-37). After the peak, most reports mentioned anxio-depressive disorders (38.8 vs 10.6% before) or sexual disorders (47.3 vs 6.9%). Other emphasised AEs were weight increase (42.3 vs 10.2%) and pain (gastrointestinal, 19.1 vs 3.5%; musculoskeletal, 22.2 vs 4.5%). CONCLUSION: This study highlighted the importance of mediatisation impact on spontaneous reporting with changes concerning amounts of reports, type of reporter, and type of reported AEs. For Mirena, this led to generate signals regarding anxio-depressive and sexual disorders.
AIMS: In 2017, concerns regarding adverse events (AEs) associated with the Mirena levonorgestrel intrauterine device were largely echoed in the media in France. This resulted in a tremendous reporting of AEs to pharmacovigilance centres. The aim of this study was to describe the reporting of AEs regarding Mirena in France and to study the impact of media coverage on this reporting. METHODS: All cases reports involving Mirena recorded in the French national pharmacovigilance database from marketing (21 July 1995) until 04 August 2017 were extracted. To allow studying the influence of mediatisation, reports were described separately for the periods preceding and following the observed media coverage peak (15 May 2017). RESULTS: Overall, 3224 reports were considered, 510 (15.8%) recorded before the media coverage peak, and 2714 (84.2%) after. Before the peak, 76.5% of reports originated from health professionals; median time-to-report was of 5.5 months (interquartile range: 1.7-18.6), and median number of AEs per report was 1 (range: 1-17). After the peak, 98.6% originated from patients; median time-to-report was 21 months (interquartile range: 8.1-45.5), and median number of AEs per report was 6 (range: 1-37). After the peak, most reports mentioned anxio-depressive disorders (38.8 vs 10.6% before) or sexual disorders (47.3 vs 6.9%). Other emphasised AEs were weight increase (42.3 vs 10.2%) and pain (gastrointestinal, 19.1 vs 3.5%; musculoskeletal, 22.2 vs 4.5%). CONCLUSION: This study highlighted the importance of mediatisation impact on spontaneous reporting with changes concerning amounts of reports, type of reporter, and type of reported AEs. For Mirena, this led to generate signals regarding anxio-depressive and sexual disorders.
Authors: David L Eisenberg; Courtney A Schreiber; David K Turok; Stephanie B Teal; Carolyn L Westhoff; Mitchell D Creinin Journal: Contraception Date: 2015-04-28 Impact factor: 3.375
Authors: Antoine Pariente; Fleur Gregoire; Annie Fourrier-Reglat; Françoise Haramburu; Nicholas Moore Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Collins Tatang; Teigna Arredondo Bisonó; Aurore Bergamasco; Francesco Salvo; Sue Ann Costa Clemens; Yola Moride Journal: Drugs Real World Outcomes Date: 2021-09-12